Gossamer Bio (GOSS) EBITDA (2018 - 2026)
Gossamer Bio (GOSS) posted quarterly EBITDA of -$44.9 million for Q1 2026, down 21.89% year-over-year from -$57.4 million in Q1 2025, and up 2.55% quarter-over-quarter from -$46.0 million in Q4 2025.
Gossamer Bio (GOSS) EBITDA (2018 - 2026) Analysis & Trends
Gossamer Bio's EBITDA history runs 9 years deep, the most recent figure standing at -$44.9 million for Q1 2026.
- In Q1 2026, EBITDA fell 21.89% year-over-year to -$44.9 million; the TTM figure through Mar 2026 stood at -$178.8 million (down 226.43% YoY), while the FY2025 annual figure was -$170.7 million, down 184.93% from the prior year.
- EBITDA for Q1 2026 stood at -$44.9 million, up from -$46.0 million in the prior quarter.
- The five-year high for EBITDA was $52.1 million in Q2 2024, with the low at -$56.0 million in Q3 2022.
- The 5-year median for EBITDA is -$46.0 million (2025), against an average of -$39.9 million.
- The sharpest annual moves came in 2024 and 2025: EBITDA soared 212.5% in 2024, then plunged 174.42% in 2025.
- Gossamer Bio's EBITDA stood at -$54.4 million in 2022, then advanced by 9.81% to -$49.0 million in 2023, then rose by 26.31% to -$36.1 million in 2024, then declined by 27.43% to -$46.0 million in 2025, then increased by 2.55% to -$44.9 million in 2026.
- Business Quant data shows GOSS's EBITDA at -$44.9 million in Q1 2026, -$46.0 million in Q4 2025, and -$49.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Gossamer Bio | 50.34 Mn | -6.69 Mn | - | -26.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -26.07 Mn |
| Mar 31, 2026 | -44.87 Mn |
| Dec 31, 2025 | -46.04 Mn |
| Sep 30, 2025 | -49.11 Mn |
| Jun 30, 2025 | -38.77 Mn |
| Mar 31, 2025 | -36.81 Mn |
| Dec 31, 2024 | -36.13 Mn |
| Sep 30, 2024 | -33.92 Mn |
| Jun 30, 2024 | 52.09 Mn |
| Mar 31, 2024 | -41.96 Mn |
| Dec 31, 2023 | -49.03 Mn |
| Sep 30, 2023 | -40.49 Mn |
| Jun 30, 2023 | -46.30 Mn |
| Mar 31, 2023 | -47.94 Mn |
| Dec 31, 2022 | -54.36 Mn |
| Sep 30, 2022 | -56.02 Mn |
| Jun 30, 2022 | -53.87 Mn |
| Mar 31, 2022 | -54.34 Mn |
| Dec 31, 2021 | -51.66 Mn |
| Sep 30, 2021 | -55.66 Mn |